Nanomedicines Targeting the Tumor Microenvironment
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
We review recent progress in cancer nanomedicine to overcome the delivery barriers in tumor microenvironment, including the understanding in the nanomedicine delivery process, stimulus-responsive delivery, and several new strategies to normalize tumor microenvironment. The application of nanomedicine in cancer immunotherapy, a renewed cancer therapy by recent breakthrough, is also highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“Several NP therapeutics, for example, Doxil (~100-nm PEGylated liposome loaded with doxorubicin) and Abraxane (~130-nm albumin-bound paclitaxel NPs), have been approved by the US Food and Drug Administration and have shown improved pharmacokinetics and reduced adverse effects compared with their parent drugs.(9,10) In…”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“The understanding of the molecular basis of immune activation, especially the research on T-cell receptors subunits and T-cell receptor costimulatory and coinhibitory molecules,(112,113) paves the path to current promising cancer immunotherapy with recent success of proof-of-concept clinical trials.(114) One prominent…”
BackgroundIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“In addition, clinical studies showed a strong association between prolonged patient survival and the presence of intratumoral CD3 or CD8 cytotoxic T cells with an interferon γ gene signature.(110,111) The understanding of the molecular basis of immune activation, especially the research on T-cell receptors subunits an…”
BackgroundThe effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149 · cited 1×
“To achieve therapeutic efficacy, NPs must first overcome systemic barriers with prolonged circulation time, especially clearance by mononuclear phagocytic system, hepatobiliary system, and urinary system.(25) Then NPs extravasate from tumor vessels and penetrate the tumor parenchyma so that even cancer cells situated…”
BackgroundNanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029 · cited 1×
“C ancer nanomedicine refers to the application of nanotechnology-based therapeutics and imaging agents for the diagnosis, monitoring, prevention, and treatment of cancer.(1) Cancer nanomedicine is expected to change the oncology by delivering a wide range of payloads with favorable pharmacokinetics, capitalizing on mo…”
Background
Cited by
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Light in diagnosis, therapy and surgery
Yun, S. H., & Kwok, S. J. J. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0008 · Cited by 793
Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy
Song, G., Cheng, L., Chao, Y., Yang, K., & Liu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201700996 · Cited by 771
Magnetic Nanoparticles in Cancer Therapy and Diagnosis
Farzin, A., Etesami, S. A., Quint, J., Memic, A., & Tamayol, A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901058 · Cited by 562
Metadata
- Authors
- Tong, R., & Langer, R.
- Venue
- The Cancer Journal
- Published
- 2015-07
- Volume
- 21
- Issue
- 4
- Pages
- 314-321
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W1937121752
- Cited by
- 80
- References
- 22
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanomedicines Targeting the Tumor Microenvironment. https://app.cochat.ai/papers/10.1097/ppo.0000000000000123
- The paper
- Tong, R., & Langer, R. (2015). Nanomedicines Targeting the Tumor Microenvironment. The Cancer Journal. https://doi.org/10.1097/ppo.0000000000000123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.